Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00251004
Status:
COMPLETED
Last Update Posted:
2011-05-10
First Post:
2005-11-07
Brief Title:
Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
Efficacy and Safety Study Comparing Concentration-controlled Everolimus in Two Doses 15 and 30 mgDay Starting Doses With Reduced Cyclosporine Versus 144 g Mycophenolic Acid as Sodium Salt With Standard Dose Cyclosporine in de Novo Renal Transplant Recipients
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study was to compare the safety and efficacy of three immunosuppressive treatment regimens following a kidney transplant
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None